Cargando…
Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in the State of Qatar
Despite the efficacy of imatinib mesylate (IM) in treating chronic myeloid leukemia (CML), there is a high degree of resistance. Alpha- 1-acid glycoprotein may reduce drug efficacy through its ability to interact with IM and blocks it from reaching its target, while protein glycoprotein (PGP) may re...
Autores principales: | Al-Dewik, Nader I., Jewell, Andrew P., Yassin, Mohammed A., Morsi, Hisham M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664201/ https://www.ncbi.nlm.nih.gov/pubmed/26640393 http://dx.doi.org/10.4137/BIC.S31427 |
Ejemplares similares
-
Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?
por: Al-Dewik, Nader I., et al.
Publicado: (2016) -
Overexpression of P‐glycoprotein and resistance to Imatinib in chronic myeloid leukemia patients
por: Ammar, Mariam, et al.
Publicado: (2020) -
Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009) -
Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014) -
Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
por: Vieira-Mion, Ana Lucia, et al.
Publicado: (2017)